A flood-damaged Pfizer joint-venture plant in India that makes injectable chemotherapy may not resume supply until mid-to-late 2028.
Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be ...
Zev A. Wainberg, MD, MSc, discussed why neither the first-line regimen nor the second-line chemotherapy comparator altered ...
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results